TuisRGLS • NASDAQ
add
Regulus Therapeutics Inc
Vorige sluiting
$8,10
Dagwisseling
$8,07 - $8,28
Jaarwisseling
$0,83 - $8,28
Markkapitalisasie
569,10 m USD
Gemiddelde volume
2,38 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | — | — |
Bedryfskoste | 3,72 m | 33,49% |
Netto inkomste | -9,63 m | -13,76% |
Netto winsgrens | — | — |
Wins per aandeel | -0,15 | 48,28% |
EBITDA | -10,45 m | -19,53% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 65,37 m | -32,99% |
Totale bates | 74,83 m | -34,44% |
Totale aanspreeklikheid | 5,80 m | -11,48% |
Totale ekwiteit | 69,03 m | — |
Uitstaande aandele | 69,23 m | — |
Prys om te bespreek | 7,79 | — |
Opbrengs op bates | -33,14% | — |
Opbrengs op kapitaal | -35,63% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -9,63 m | -13,76% |
Kontant van bedrywe | -10,61 m | -21,40% |
Kontant van beleggings | 21,50 m | 127,37% |
Kontant van finansiering | 45,00 k | -99,95% |
Netto kontantverandering | 10,93 m | 87,87% |
Beskikbare kontantvloei | -6,34 m | -1,31% |
Meer oor
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. In April 2025, Novartis announced that it had entered into an agreement to acquire Regulus. Wikipedia
Gestig
Sep. 2007
Webwerf
Werknemers
34
